最近の業績（2020年〜2023年）

論文

• Fujiki F, Morimoto S, Nishida Y, Inoue K, Tanii S, Aoyama N, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Oji Y, Sogo S, Sugiyama H. Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs. Cancer Immunol Immunother, 2023 Mar 20. doi: 10.1007/s00262-023-03420-8.
• Oji Y, Kagawa N, Arita H, Naka N, Hamada K, Outani H, Shintani Y, Takeda Y, Morii E, Shimazu K, Suzuki M, Nishida S, Nakata J, Tsuboi A, Iwai M, Hayashi S, Imanishi R, Ikejima S, Kanegae M, Iwamoto M, Ikeda M, Yagi K, Shimokado H, Nakajima H, Hasegawa K, Morimoto S, Fujiki F, Nagahara A, Tanemura A, Ueda Y, Mizushima T, Ohmi M, Ishida T, Fujimoto M, Nonomura N, Kimura T, Inohara H, Okada S, Kishima H, Hosen N, Kumanogoh A, Oka Y, Sugiyama H. WT1 Trio Peptide-Based Cancer Vaccine for Rare Cancers Expressing Shared Target WT1. Cancers(Basel), 15(2):393, 2023.
• Fujiki F, Morimoto S, Katsuhara A, Okuda A, Ogawa S, Ueda E, Miyazaki M, Isotani A, Ikawa M, Nishida S, Nakajima H, Tsuboi A, Oka Y, Nakata J, Hosen N, Kumanogoh A, Oji y, Sugiyama H. T cell-intrinsic vitamin A metabolism and its signaling are targets for memory T cell-based cancer immunotherapy. Frontiers in Immunology, 13:935465, 2022.
• Koya T, Niida Y, Togi M, Yoshida K, Sakamoto T, Ura H, Togi S, Kato T Jr, Yamada S, Sugiyama H, Koido S, Shimodaira S. The Detection of Immunity against WT1 and SMAD4P130L of EpCAM+ Cancer Cells in Malignant Pleural Effusion. Int J Mol Sci, 23(20):12177, 2022.
• Alzaaqi S, Naka N, Hamada K, Hosen N, Kanegae M, Outani H, Adachi M, Imanishi R, Morii E, Iwai M, Nakata J, Fujiki F, Morimoto S, Nakajima H, Nishida S, Tsuboi A, Oka Y, Sugiyama H, Oji Y. WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine. Oncol Lett. 23(2):65, 2022.
• Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain.
  Hasegawa K, Ikeda S, Yaga M, Watanabe K, Urakawa R, Iehara A, Iwai M, Hashiguchi S, Morimoto S, Fujiki F, Nakajima H, Nakata J, Nishida S, Tsuboi A, Oka Y, Yoshihara S, Manabe M, Ichihara H, Mugitani A, Aoyama Y, Nakao T, Hirose A, Hino M, Ueda S, Takenaka K, Masuko T, Akashi K, Maruno T, Uchiyama S, Takamatsu S, Wada N, Morii E, Nagamori S, Motooka D, Kanai Y, Oji Y, Nakagawa T, Kijima N, Kishima H, Ikeda A, Ogino T, Shintani Y, Kubo T, Mihara E, Yusa K, Sugiyama H, Takagi J, Miyoshi E, Kumanogoh A, Hosen N.
  Sci Transl Med. 2022 Feb 16;14(632):eaax7706. doi: 10.1126/scitranslmed.aax7706.
• Ito M, Oji Y, Adachi M, Imanishi R, Alzaaqi S, Hiwasa T, Oshima Y, Yajima S, Suzuki T, Nanami T, Sumazaki M, Shiratori F, Funahashi K, Sugiayama H, Shimada H. Serum WT1-271 IgM antibody as a novel diagnostic marker for Gastric Cancer. Mol Clin Oncol. 16(3):74, 2022.
• Yokota C, Nakata J, Takano K, Nakajima H, Hayashibara H, Minagawa H, Chiba Y, Hirayama R, Kijima N, Kinoshita M, Hashii Y, Tsuboi A, Oka Y, Oji Y, Kumanogoh A, Sugiyama H, Kagawa N, Kishima H. Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies. Neurooncol Adv. 2021 Jun 29;3(1):vdab091.
• therapies. Neurooncol Adv, 3(1):vdab091, 2021. 262.
  Neurooncol Adv. 2021 Jun 29;3(1):vdab091. doi: 10.1093/noajnl/vdab091. eCollection 2021 Jan-Dec.
• Nishida S, MorimotoS, Oji Y, Shirakata T, Enomoto T, Tsuboi A, Ueda Y, Yoshino K, Shouqc A, Kanegae M, Ohno S, Fujikie F, Nakajima H, Nakae Y, Nakata J, Hosen N, Kumanogoh A, Oka Y, Morita S, Kimura T, Sugiyama H. Cellular and humoral immune responses induced by a human leukocyte antigen–restricted class I peptide cancer vaccine targeting Wilms' tumor gene 1 affects clinical outcomes in advanced ovarian cancer. J Immunother. 45(1):56-66, 2022.
• Yokota C, Takano K, Chiba Y, Kagawa N, Tsuboi A, Oka Y, Oji Y, Kinoshita M, Kijima N, Kishima H, Izumoto S, Sugiyama H, Hashimoto N. Maintenance of WT1 expression in tumor cells is associated with good prognosis in malignant glioma patients treated with WT1 peptide vaccine immunotherapy. Cancer Immunol, Immunother, 71(1):189-201, 2022.
• Yokota C, Nakata J, Takano K, Nakajima H, Hayashibara H, Minagawa H , Chiba Y, Hirayama R, Kijima N, Kinoshita M, Hashii Y, Tsuboi A, Oka Y, Oji Y, Kumanogoh A, Sugiyama H, Kagawa N, Kishima H. Distinct difference in tumor-infiltrating immune cells between Wilms' tumor gene 1 peptide vaccine and anti-programmed cell death-1 antibody therapies. therapies. Neurooncol Adv, 3(1):vdab091, 2021. 262.
• Nakajima H, Nakata J, Imafuku K, Hayashibara H, Isokawa K, Udaka K, Fujiki F, Morimoto S, Hasegawa K, Hosen N, Hashii Y, Nishida S, Tsuboi A, Oka Y, Oji Y, Sogo S, Sugiyama H. Identification of mouse helper epitopes for WT1-specific CD4+ T cells. Cancer Immunol Immunother, 70(11):3323-3335, 2021.
• Kiryu S, Ito Z, Suka M, Bito T, Kan S, Uchiyama K, Saruta M, Hata T, Takano Y, Fujioka S, Misawa T, Yamauchi T, Yanagisawa H, Sato N, Ohkusa T, Sugiyama H, Koido S. Prognostic value of immune factors in the tumor microenvironment of patients with pancreatic ductal adenocarcinoma. BMC Cancer, 21(1):1197, 2021
• Nakata J, Isohashi K, Oka Y, Nakajima H, Morimoto S, Fujiki F, Oji Y, Tsuboi A, Kumanogoh A, Hashimoto N, Hatazawa J, Sugiyama H. Imaging Assessment of Tumor Response in the Era of Immunotherapy. Diagnostics (Basel), 11(6): 1041, 2021.
• Fujiki F, Tsuboi A, Morimoto S, Hashimoto N, Inatome M, Nakajima H, Nakata J, Nishida S, Hasegawa K, Hosen N, Oka Y, Oji Y, Sogo S, Sugiyama H. Identification of two distinct populations of WT1-specific cytotoxic T lymphocytes in co-vaccination of WT1 killer and helper peptides. Cancer Immunol Immunother. 70(1):253-263, 2021.
• Hashii Y, Oka Y, Kagawa N, Hashimoto N, Saitou H, Fukuya S, Kanegae M, Ikejima S, Oji Y, OzonoK, Tsuboi A, Sugiyama H. Encouraging clinical evolution of a pediatric patient with relapsed diffuse midline glioma who underwent WT1-targeting immunotherapy: A case report and literature review. Frontiers in Oncology, 10:1188, 2020.
• Maeda T, Nagano S, Kashima S, Terada K, Agata Y, Ichise H, Ohtaka M, Nakanishi M, Fujiki F, Sugiyama H, Kitawaki T, Kadowaki N, Takaori-Kondo A, Masuda K, Kawamoto H. Regeneration of tumor antigen-specific cytotoxic 1 T lymphocytes from iPSCs transduced with exogenous TCR genes. Mol Ther Methods Clin Dev. 19:250-260, 2020
• Nakata J, Isohashi K, Morimoto S, Itou R, Komiya T, Matsuura A, Nakajima H, Fujiki F, Nishida S, Hashii Y, Hasegawa K, Nakatuka S, Hosen N, Tsuboi A, Oka Y, Kumanogoh A. Shibano M, Munakata S, Oji Y, Hatazawa J, Sugiyama H. Enhanced immune reaction resulting from co-vaccination of WT1 helper peptide assessed on PET-CT. Medicine, 99(39): e22417, 2020.
• Nagai K, Adachi T, Harada H, Eguchi S, Sugiyama H, Miyazaki Y. Dendritic cell-based immunotherapy pulsed with Wilms Tumor 1 peptide and MUC-1 as an adjuvant therapy for pancreatic ductal adenocarcinoma after curative resection: a PhaseI /IIa clinical trial. Anticancer Res, 40(10):5765-5776, 2020.
• Shin Kan Tsuuse Bito, Shimabuku M, Taguchi J, Ohkusa T, Shimodaira S, Sugiyama H, Koido S. Impact of mature dendritic cells pulsed with a novel WT1 helper peptide on the induction of HLA‑A2‑restricted WT1‑reactive CD8+ T cells. Int J Oncol, 57(4) :1047-1056, 2020.
• Hayashi S, Imanishi R, Adachi M, Ikejima S, Nakata J, Morimoto S, Fujiki F, Nishida S, Tsuboi A, Hosen N, Nakajima H, Hasegawa K, Oka Y, Sugiyama H, Oji Y. Reader-free ELISPOT assay for immuno-monitoring in peptide-based cancer vaccine immunotherapy. Biomed Rep. 12(5):244-250, 2020.
• Koya T, Date I, Kawaguchi H, Watanabe A, Sakamoto T, Togi M, Kato T Jr, Yoshida K, Kojima S, Yanagisawa R, Koido S, Sugiyama H, Shimodaira S. Dendritic Cells Pre-Pulsed with Wilms' Tumor 1 in Optimized Culture for Cancer Vaccination. Pharmaceutics. 12(4):305, 2020.

• 過去の業績（2019年以前）はこちら